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Hyperkalaemia is a life-threatening condition, resulting from decreased renal func-
tion or dysfunctional homoeostatic mechanisms, often affecting patients with cardio-
vascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors
(RAASi) are known to improve outcomes in CV patients but can also cause drug-
induced hyperkalaemia. New therapeutic options exist to enhance potassium excre-
tion in these patients. To this aim, we reviewed pharmacological properties and
available data on patiromer and sodium zirconium cyclosilicate for the treatment of
hyperkalaemia. These agents have been shown in randomized trials to signiﬁcantly
reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-
aldosterone system inhibitors. Additional research should focus on their long-term
effects/safety proﬁles and drug–drug interactions.
Introduction
Hyperkalaemia, i.e. serum potassium concentrations above
5.0 mEq/L, is a very common condition in cardiovascular
(CV) patients, resulting from different causes such as in-
creased potassium intake, impaired distribution between
the intracellular and extracellular spaces, and/or reduced
renal excretion.1 Hyperkalaemia is particularly prevalent
in patients older than 65years with advanced chronic kid-
ney disease (CKD), diabetes, and/or chronic heart failure.2
Of note, elevation in potassium may be induced by drugs
that modulate potassium excretion such as angiotensin-
converting enzyme inhibitors, renin-angiotensin-
aldosterone system inhibitors (RAASi), beta-adrenergic
receptor antagonists; angiotensin receptor blockers; min-
eralocorticoid receptor antagonists.3 In clinical practice,
hyperkalaemia is a crucial limitation to fully titrate RAASi.4
Patients with severe hyperkalaemia are at higher risk of
mortality, as it may lead to abnormalities in cardiac depo-
larisation/repolarisation and contractility, resulting in car-
diac arrhythmias, and ultimately to sudden cardiac death.2
To avoid these severe outcomes, treatment for lowering
potassium levels should be initiated as early as possible.5
Taking into account these issues, here, we summarize
the interventions able to improve hyperkalaemia with a
particular focus on new treatments such as patiromer and
sodium zirconium cyclosilicate (SZC).
Current therapies for hyperkalaemia
Pharmacological characteristics of treatments for hyperka-
laemia according to current guidelines6–8 are summarized
in Table 1. Briefly, management of acute hyperkalaemia
includes reducing dietary potassium and withdrawal of ex-
acerbating drugs; administration of intravenous calcium
gluconate, insulin, and glucose; nebulized albuterol; cor-
rection of acidosis with sodium bicarbonate to transfer po-
tassium into the cells.5 Loop diuretics and potassium
binders, i.e. sodium polystyrene sulfonate (SPS) and
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calcium polystyrene sulfonate (CPS) can be used to pro-
mote the excretion via renal or gastrointestinal route, re-
spectively. If all these measures are ineffective,
haemodialysis may be needed.
Unfortunately, these treatments present some limita-
tions. The use of SPS and CPS is often associated with ad-
verse effects and their efficacy is uncertain.9,10 Other
treatments, i.e. insulin/dextrose and beta-receptor ago-
nists like salbutamol, are not yet approved in some EU
countries and present several limitations as well. In partic-
ular, their effects are transient and rebound hyperkalaemia
can occur after 2 h.5
The management of chronic hyperkalaemia poses fur-
ther challenge. Adverse gastrointestinal effects makes
long-term administration difficult. Further, dietary restric-
tions must be maintained over time, and long-term cessa-
tion of potassium retaining agents is detrimental on CV/
renal outcomes.5 The ESC heart failure guidelines recom-
mend that if a withdrawal of these drugs is needed, it
should be kept at minimum, and RAASi should be cautiously
re-established as soon as possible while monitoring potas-
sium levels.11
Considering all these limitations, new therapeutic
options for the chronic management of patients with
hyperkalaemia are warranted. To this aim, oral therapies
such as patiromer calcium and SZC have been recently
developed.
New treatments for hyperkalaemia:
patiromer calcium and sodium zirconium
cyclosilicate
Patiromer calcium and SZC are two new polymer-based,
non-systemic agents formulated to increase potassium re-
duction via the gastrointestinal tract. Table 2 compares
their pharmacodynamic and pharmacokinetic properties.
Patiromer
Pharmacological properties and available data
Patiromer is an oral potassium binder, a novel next-
generation spherical non-absorbed polymer, recently ap-
proved by the FDA for the treatment of chronic
hyperkalaemia.
Its mechanism of action has been described in detail
elsewhere.12 Briefly, the patiromer polymer has a low mo-
lecular weight, providing a higher absolute binding capac-
ity. Also, patiromer is characterized by a minimal water
absorption and the exchange cation involves calcium and
not sodium.13 For this reason, it is a preferable choice for
Table 1 Pharmacology of current treatments for hyperkalaemia
Mechanism of action Adverse effects
SPS/CPS Removal Nausea, constipation, diarrhoea, paralytic
ileus, cecal perforation, hypercalcaemia,
hypernatraemia
Onset: 60–180 min
Duration: 240–360
Kþ reduction: 0.5–1.0 per 1 g resin
Haemodialysis Removal Hypokalaemia, arrhythmias
Onset: <10 min
Duration: <60–180
Kþ reduction : 1.2–1.5/h
Loop diuretic (furosemide) Removal Ototoxicity, hypokalaemia, nephrotoxicity
Onset: immediate 15 min
Duration: 120–180
Insulin þ dextrose Translocation Hypoglycaemia, hyperosmolarity,
volume overloadOnset: <15–30 min
Duration: 240–360
Kþ reduction: 0.5–1.5 mEq/L (dose-dependent)
Beta-adrenergic agonists Translocation Tremor, tachycardia
Onset: 3–5 min onset
Duration: 1–4 h
Kþ reduction: 1.6–1.7/2 h (salbutamol)
Sodium bicarbonate
(only in patients with
metabolic acidosis—
bicarbonate <22mEq/L)
Translocation (doubt effect) Hypernatraemia, volume overload,
tetany, hypertensionCorrection of acidosis
Onset: 30–60 min (onset).
Duration: 2–6 h
Calcium gluconate Translocation Hypercalcaemia, tissue necrosis
Stabilise myocardium, protect cardiomycytes
Onset: 1–3 min
Duration: 30–60 min
Kþ reduction: 0.5–1.5 mEq/L
CPS, calcium polystyrene sulfonate; Kþ, potassium; SPS, sodium polystyrene sulfonate.
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patients who cannot tolerate even small increases in so-
dium load. A study12 showed that patiromer is not systemi-
cally absorbed, also demonstrating its lack of systemic
bioavailability. In particular, patiromer is fully ionized at
the physiological pH of the colon, where the concentration
of potassium in the gastrointestinal tract is the highest,
thus providing optimal ion exchange. It decreases serum
potassium via an increase in faecal excretion. In a Phase 1
study on 33 healthy participants,12 patiromer increased
faecal and decreased urinary potassium excretion, remain-
ing physically stable during passage through the gastroin-
testinal tract. The fact that the patiromer polymer is not
absorbed is a major contributing factor for its safety profile
(see below).14
Three main clinical trials (PEARL-HF,15 OPAL-HK,16 and
AMETHYST-DN17) examined the safety and efficacy of
patiromer in patients with hyperkalaemia as summarized
in Table 3. All three studies achieved their primary
endpoints and reduced serum potassium in patients with
CKD, Type 2 diabetes mellitus, hypertension, and/or heart
failure. Thus, available data collected so far show
patiromer to be effective in decreasing serum potassium,
preventing recurrence of hyperkalaemia and reducing
RAASi discontinuation.14 A recent substudy of the OPAL-
HK18 conducted in older CKD patients taking RAASi, found
that patiromer reduced recurrent hyperkalaemia and was
well tolerated also in this subgroup.
Drug–drug interactions and adverse events
Because patiromer is not systemically absorbed, drug–drug
interactions related to cytochrome P450 or systemic drug
transporter effects are uncommon.19 Patiromer showed no
significant binding with many oral drugs, commonly used in
patients with hyperkalaemia.19 However, interactions
with patiromer in the gastrointestinal tract may occur, re-
ducing absorption of concomitant oral medications. For
Table 2 Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate and patiromer
SZC Patiromer
Form Powder for oral suspension:
5 g/sachet
10 g/sachet
Powder for oral suspension:
8.4 g/packet
16.8 g/packet
25.2 g/packet
Dosage Initial: 10 g PO TID for up to 48 h
Maintenance: 5 g to 10 g PO once daily or 5 g
every other day
Initial: 8.4 g PO qDay
Maintenance: may increase or decrease
dose as necessary; not to exceed 25.2 g
qDay
May be uptitrated upwards at 1week or lon-
ger intervals, in increments of 8.4 g
Doses exceeding 50.4 g/day have not been
tested; excessive doses may result in
hypokalaemia; restore serum potassium if
hypokalaemia occurs
Adverse effects Oedema (6%)
Hypokalaemia (4%)
Constipation (7.2%)
Hypomagnesaemia (5.3%)
Diarrhea (4.8%)
Hypokalaemia, <3.5 mEq/L (4.7%)
Nausea (2.3%)
Abdominal discomfort (2%)
Flatulence (2%)
Mechanism of action Potassium binder and remover
Captures and removes potassium from the
GI tract
Increases faecal potassium excretion
Potassium binder
Removal. Binds and removes potassium from
the GI tract, particularly the colon
Increases faecal potassium excretion
Contraindications/cautions Avoid with severe constipation or bowel ob-
struction or impaction, including abnormal
post-operative bowel motility disorders
Drug interactions: transient increase in gas-
tric pH
Avoid with severe constipation or bowel ob-
struction or impaction, including abnormal
postoperative bowel motility disorders
Monitor for hypomagnesemia
Patiromer binds many orally administered
medications
Limitations Not to be used as an emergency treatment
for life-threatening hyperkalaemia be-
cause of its delayed onset of action
Not to be used as an emergency treatment
for life-threatening hyperkalaemia be-
cause of its delayed onset of action
Absorption Not systemically absorbed Not systemically absorbed
Elimination Excretion: faeces Excretion: faeces
GI, gastrointestinal; PO, per os (per mouth); qDay, one a day; TID, three times a day.
Data from FDA-approved labelling information.
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this reason, it is advised to separate their administration
by at least 3 h.19 A study20 showed that amlodipine, cina-
calcet, clopidogrel, furosemide, lithium, metoprolol, tri-
methoprim, verapamil, and warfarin had no clinically
significant interactions with patiromer and that ciprofloxa-
cin, levothyroxine, and metformin had no clinically signifi-
cant drug–drug interactions after separating their
administration from that of patiromer by 3h. Of note, two
of these drugs (ciprofloxacin and levothyroxine) are known
to interact with calcium. It is therefore recommended to
separate concomitant medications containing calcium.20
Further studies are needed to evaluate drug–drug inter-
actions of patiromer with quinidine and thiamine.
As for adverse events, the aforementioned clinical stud-
ies showed that patiromer was not associated with serious
adverse events. Adverse events were similar among trials.
The most commonly reported adverse events were gastro-
intestinal effects (i.e. constipation and diarrhoea) and
electrolyte abnormalities (i.e. hypomagnesaemia)
(Table 2), as also shown by a recent review and meta-
analysis.21 Taken all together, these data show patiromer
to be well tolerated.13
Sodium zirconium cyclosilicate
Pharmacological properties and available data
A report by the EMA (25 January 2018-EMA/93250/2018-
Committee for Medicinal Products for Human Use) stated
that SZC is indicated for the treatment of hyperkalaemia in
adult patients. Pharmacological properties of SZC have
been described in detail elsewhere22 and are summarized
in Table 2. Briefly, this agent is an inorganic cation ex-
change crystalline compound that allows a thermodynami-
cally favourable catching of potassium ions.23 It acts within
1 h of administration by permanently removing excess po-
tassium in the gastrointestinal tract.22 Sodium zirconium
cyclosilicate is mainly excreted in the faeces and not
systemically absorbed.23 The recommended initial dose is
10 g three times a day for up to 48 hours.
Clinical trials demonstrated a dose-dependent potas-
sium-lowering effect of SZC (Table 4). In particular, the
HARMONIZE trial24 found that normokalaemia was
achieved by 84% of patients within 24 h and by 98% of
patients within 48 h. After 28 days, potassium level was
significantly lower in all three SZC groups (i.e. 5 g, 10 g or
15 g) than placebo group and these reductions were dose-
dependent.
Similar results were gained by a subgroup analysis25 of
this trial, conducted on 87 patients with heart failure, in
whom serum potassium decreased to physiological levels
within 48h (Table 4).
A multicentre, two-stage, double-blind, and Phase 3
trial26 found that SZC led to a dose-dependent reduction of
potassium level within 48h. A significant difference was
found between the 2.5 g, 5 g, and 10g groups when com-
pared with placebo. Patients who reached normokalaemia
(72%) were then randomized to receive either their original
SZC dose or placebo. Results showed that patients receiv-
ing ZS-9.5 g and 10g maintained normokalaemia during 3–
14 days.
A Phase 2 randomized, double-blind, placebo-control-
led, and dose-escalating clinical trial27 in advanced CKD
(Table 4) showed the efficacy of SZC in the 3 g and 10 g
dosages.
Unfortunately, all these studies are limited by their short
duration. An ongoing study is evaluating SZC safety and ef-
ficacy for up to 12months with a 10g standard dose to be
adjusted in increments of 5 g.
Of note, SZC should not be used for the acute treatment
of hyperkalaemia, as these patients were excluded from
both trials.22 On the other hand, it may be used as preven-
tive treatment in patients with CKD or patients maintained
onmedications that affect potassium level.22
Table 3 Main clinical trials on patiromer for the treatment of hyperkalaemia
Study (ref.) Patients included Primary endpoint(s) Main results
PEARL-HF: Phase 2, prospec-
tive, randomized, double-
blind, placebo-controlled,
parallel-group clinical
trial15
Patients with chronic HF and a
history of hyperkalaemia or
CKD
Change from baseline in serum
Kþ at the end of treatment
Lower serum Kþ levels, lower
incidence of hyperkalaemia
AMETHYST-DN: Phase 2, pro-
spective, randomized,
open-label, dose-ranging
clinical trial17
Outpatients with hyperkalae-
mia, Type 2 diabetes mellitus,
and CKD receiving an ACEi,
ARB, or both (n ¼ 306)
Decline in Kþ concentration
from baseline to Week 4 or
prior to dose-titration
Decreases in serum Kþ levels
were observed at each
monthly point, lasting
through 52weeks
OPAL-HK: Phase 3, two-phase,
single-blind, randomized,
placebo-controlled trial 16
Initial phase: patients with
Stage 3 or 4 CKD and hyperka-
laemia stabilized on an RAASi
(n ¼ 243)
Initial phase: mean change in
the serum potassium level
from baseline to Week 4
Decrease in serum potassium
levels and reduction in the
recurrence of
hyperkalaemia
Randomized phase: patients
who reached the target po-
tassium level (n ¼ 107)
Randomized phase: between
group difference in the me-
dian change in the serum po-
tassium level
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; HF, heart failure; RAASi, renin–an-
giotensin–aldosterone system inhibitor.
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Drug–drug interactions and adverse events
Drug–drug interactions have not been fully investigated. Of
note, this agent can transiently increase gastric pH and
should be administered at least 2 h after or before other
oral medications as suggested by the EMA. However, this
separation is only needed if the concomitant drug displays
pH-dependent solubility, i.e. highly soluble in acidic pH,
leading to faster drug release.
Except for rare, controllable events such as urinary
tract infections (1.1%) and oedema (0.9%), a recent meta-
analysis21 found that safety profile of SZC is similar to that
of placebo.
Long-term clinical trials are needed to assess possible
risks thatmay be related to SZC during chronic use.
Conclusions and suggestions for upcoming
studies
Clinical studies of patiromer and SZC demonstrated a dose-
dependent potassium-lowering effect for both these
agents. They may be helpful in optimizing RAASi therapies
in patients with hyperkalaemia. However, their benefits on
long-term outcomes should be further evaluated in proper
clinical trials. Although there are some concerns about
hypomagnesaemia and positive calcium balance from
patiromer, and sodium overload from SZC, both agents
have been shown to be well tolerated.9
Upcoming clinical trials should aim to investigate
whether these new treatments for hyperkalaemia could
plausibly improve clinical outcomes in specific patient
groups that are prone to arrhythmias (e.g. patients with
pre-existing CV disease, or patients with advanced
CKD).28
Despite these gaps of knowledge, in light of their phar-
macological properties and available evidence collected so
far, patiromer and SZC are promising agents in the manage-
ment of hyperkalaemia in CV patients.
Conflict of interest: none declared.
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